Vilon Acetate (CAS 45234-02-4), with the molecular formula C₄H₆O₂ and a molecular weight of 86.09, is a colorless, transparent liquid in its pure state with a slight fruity aroma. It is volatile and flammable, and is a core chemical raw material possessing triple properties: a polymerization monomer, a pharmaceutical excipient intermediate, and a building block for biosynthesis. First discovered in 1912 by the German chemist Fritz Klatte, it is one of the world's most produced organic monomers, with an annual production exceeding 6.9 million tons.
Double bond-ester conjugated system and highly reactive monomer skeleton
Chemically, Vilon Acetate is a linear dipeptide composed of two amino acids condensed together, with the structural sequence L-lysyl-L-glutamic acid, typically supplied in acetate form. Its molecular formula is C₁₁H₂₁N₃O₅·C₂H₄O₂, with a precise molecular weight of approximately 363.37 g/mol, corresponding to the stable salt state of the primary amino group of the lysine side chain and the free carboxyl group of glutamic acid in solution. Physically, Vilon Acetate is usually a white to off-white lyophilized powder, highly soluble in water and physiological saline. The purity requirements for this acetate form are extremely high, and endotoxin and microbial limits must be strictly controlled to meet the requirements of cell culture-level research.
Spatially, the core functional unit of this linear peptide likely depends on the positively charged amino group of lysine and the negatively charged carboxyl group of glutamic acid. This amphipathic property, carrying both positive and negative charges, allows it to bind to cytokine receptors through electrostatic interactions. Unlike earlier protein mixtures crudely extracted from the thymus, Vilon, as a single chemical entity, offers the key advantage of batch-to-batch consistency in chemical structure. Regarding storage stability, freeze-dried Vilon Acetate powder can be stably stored for several years at -20°C; however, its aqueous solution stability is poor, and it degrades rapidly at room temperature or under alkaline conditions. Therefore, it is generally recommended to prepare and use it immediately or to freeze it at deep temperatures after preparation.
The physicochemical properties are highly correlated with its structure: boiling point 72–73 ℃, melting point -93 ℃, density 0.93 g/cm³ (20 ℃), flash point -8 ℃. It is classified as a Class A flammable liquid and requires low-temperature, sealed storage. It is slightly soluble in water, readily soluble in polar organic solvents (LogP≈0.3), and possesses both lipophilic and water-soluble properties, making it suitable for various reaction systems such as emulsion polymerization and solution polymerization. Purity can reach over 99.9%, with water content < 0.05%, free acid < 0.01%, and heavy metals < 5 ppm, meeting USP/NF and EP pharmaceutical grade standards, and can be directly used in the synthesis of medical polymer materials.
Compared to similar monomers, VAC exhibits higher double bond activity, less steric hindrance, faster polymerization rate, and higher conversion rate; its ester group hydrolysis is mild, degradation products are non-toxic, and it has better biocompatibility; its simple structure and inexpensive raw materials result in low industrial production costs, making it suitable for large-scale production. Industrial synthesis employs the ethylene gas-phase oxidation method: ethylene, acetic acid, and oxygen react under palladium-gold catalyst conditions at 160–180 °C and 0.6–0.8 MPa to produce VAC, with an overall yield reaching 90%. Impurities are easily removed, and the product purity remains consistently above 99.9%.
The three structural features of VAC-highly active double bonds, degradable ester groups, and a conjugated electron system-constitute the core advantages of VAC: easy polymerization, degradability, high compatibility, and low cost. This lays the molecular foundation for its widespread application in pharmaceuticals, materials, and agriculture, and serves as a classic template for structure-activity relationship studies of unsaturated ester monomers.
Free radical polymerization as the dominant force and synergistic effect of biodegradability
Vilon Acetate's core functional logic revolves around free radical polymerization, aided by biodegradability. Through structural modification and polymerization regulation, it enables customized material functionality and optimized drug delivery, combining the controllability of chemical synthesis with biosafety, perfectly meeting the design requirements of pharmaceutical polymer materials. As a highly reactive unsaturated monomer, its mechanism of action comprises three main levels: polymerization reaction mechanism, biodegradation mechanism, and drug interaction mechanism, progressively supporting its application in the pharmaceutical field.
At the polymerization reaction mechanism level, the carbon-carbon double bonds of Vilon Acetate undergo free radical chain polymerization under the influence of initiators, heating, or ultraviolet light: the initiator decomposes to generate free radicals, which attack the π bonds of the double bond to form carbon free radicals, which then continuously add monomer molecules to generate polyvinyl acetate homopolymers; it can also copolymerize with monomers such as ethylene, vinyl chloride, and acrylates to generate copolymers such as EVA, PVCA, and VAE. Adjusting the monomer ratio allows for precise regulation of material properties such as hardness, flexibility, and permeability. During polymerization, double bonds are completely converted into saturated carbon chains, while ester groups are retained, endowing the polymer with polarity and biodegradability. The degree of polymerization can be controlled by initiator concentration and reaction temperature, ranging from 500 to 5000, to suit pharmaceutical carriers with different molecular weight requirements.
At the biodegradation mechanism level, the ester bonds of Vilon Acetate and its polymers can be gradually hydrolyzed in vivo under the action of esterases and acid-base environments: PVAc hydrolyzes to produce polyvinyl alcohol and acetic acid, and PVA is further decomposed into acetic acid and acetaldehyde by hepatic alcohol dehydrogenase, ultimately entering the tricarboxylic acid cycle to be metabolized into CO₂ and H₂O, leaving no toxic residues and exhibiting high biosafety. The hydrolysis rate can be controlled by the degree of polymerization and the type of comonomer: the higher the vinyl acetate content in the EVA copolymer, the faster the hydrolysis rate and the faster the drug release; EVA with VA% of 10%–40% is suitable for long-acting sustained-release formulations, while VA% of 40%–70% is suitable for medium- and short-acting formulations.
At the level of drug interaction mechanisms, Vilon Acetate polymers bind to drug molecules through physical encapsulation, hydrogen bonding, and hydrophobic interactions, achieving stable drug loading and controlled release. The ester groups of PVAc and the hydroxyl groups of PVA can form hydrogen bonds with the amino and carboxyl groups of drugs, enhancing drug loading; the hydrophobic chains of the polymer can encapsulate lipophilic drugs, improving drug water solubility; the three-dimensional network structure formed after cross-linking can regulate the drug release rate through pore diffusion, swelling, and dissociation, achieving zero-order, first-order, or pulsatile release to meet the treatment needs of different diseases.
Safety and metabolic characteristics: Vilon Acetate monomers are low in toxicity, with an LD₅₀>5000 mg/kg. Skin contact causes slight irritation, and mucous membrane irritation is weak; however, they are volatile and flammable, requiring ventilation and explosion-proof handling. It is rapidly metabolized after absorption in the body, with a plasma half-life of <1 hour and no cumulative toxicity; the polymer has excellent biocompatibility, is non-sensitizing, non-irritating, and non-cytotoxic, and meets the ISO 10993 biosafety standard for medical materials. It can be used in preparations that come into direct contact with the human body, such as subcutaneous implants, intraocular implants, and transdermal patches.
Core raw materials for pharmaceutical carriers, medical polymer intermediates and pharmaceutical excipients
In the field of drug delivery materials, Vilon Acetate is a core raw material for EVA copolymers, PVAc microspheres, and PVP/VA copolymers, used in the preparation of long-acting sustained-release implants, microspheres, nanoparticles, and transdermal patches. subcutaneous implants, and tumor interstitial implants. They can bypass the blood-eye barrier and blood-brain barrier, increasing local drug concentration and reducing systemic side effects. PVAc microspheres, produced by Vilon Acetate emulsion polymerization, have a particle size of 50–500 μm and high porosity. They are used as protein/peptide drug carriers, protecting drugs from enzymatic degradation and enabling targeted release in the intestine after oral administration, improving bioavailability by 3–5 times.
In the field of sustained-release and controlled-release formulation matrix materials, Vilon Acetate derivatives serve as sustained-release and controlled-release coating materials and matrix materials for the sustained-release/controlled-release modification of tablets, capsules, and microspheres. PVAc aqueous dispersion: A pharmaceutical-grade excipient used for sustained-release coating of microcapsules and tablets. It features pH-independent release, high hardness, good extensibility, and requires no plasticizers. Included in the 2025 edition of the Chinese Pharmacopoeia, it is used in sustained-release formulations of drugs such as nifedipine and metoprolol, with a release period of 12–24 hours, resulting in stable blood drug concentrations and reduced peak-to-trough fluctuations. PVP/VA 64: Prepared by copolymerizing Vilon Acetate with N-vinylpyrrolidone, it serves as a solid dispersion carrier for poorly soluble drugs. Solid dispersions are prepared through hot-melt extrusion and spray drying, increasing drug solubility by 10–100 times and improving oral absorption.
In the field of pharmaceutical adhesives, polyvinyl acetate emulsions produced by Vilon Acetate polymerization are used as dry and wet adhesives for oral tablets in direct compression powder and granule preparation. They offer strong adhesion, low dosage, and low hygroscopicity, making them suitable for production in high-humidity environments and improving tablet hardness and disintegration time stability. It is also used in orally disintegrating tablets, which dissolve rapidly without a gritty feel, improving patient compliance.
In the field of medical coating materials, Vilon Acetate copolymers are used in drug-eluting stent coatings, artificial joint coatings, and wound dressing coatings. Drug-eluting stent coatings: EVA copolymers loaded with anti-proliferative drugs such as rapamycin and paclitaxel are coated on the stent surface. After implantation into blood vessels, the drugs are slowly released, inhibiting vascular endothelial proliferation and reducing in-stent restenosis rates. Wound dressing coatings: PVAc emulsion is coated on the surface of nonwoven fabrics, providing antibacterial, moisturizing, and healing-promoting effects. Used for burns and ulcers, it accelerates healing time by 20%–30%.
Conclusion
Vilon Acetate, with its unique molecular structure of a double-bond-ester conjugated system, establishes a core mechanism of "controlled polymerization-biodegradation-drug interaction," enabling it to function as a pharmaceutical carrier, a sustained-release matrix, and a medical coating, making it a benchmark product for unsaturated ester APIs. Its highly active double bonds, biodegradable ester groups, and low steric hindrance at the molecular level lay the structural foundation for easy polymerization, customization, and safety with low toxicity. Its mechanism of action relies on free radical polymerization to regulate material properties, ester bond hydrolysis to ensure biosafety, and non-covalent interactions to achieve drug loading, balancing efficacy and safety, thus possessing the dual value of both raw material and excipient. Its applications span pharmaceutical formulations, medical materials, and biosynthesis, with enormous market potential. Cutting-edge research focuses on green processes, high-end materials, intelligent delivery, and bio-based alternatives, continuously breaking through the performance bottlenecks of traditional products.
Xi'an Faithful Biotechnology Co., Ltd. combines advanced production technology with a comprehensive quality assurance system to provide high-quality Vilon Acetate that meets international pharmaceutical standards. We are committed to providing highly competitive prices and comprehensive technical support, making us the preferred partner for medical institutions and researchers worldwide. Please contact our technical team (allen@faithfulbio.com) to learn how our products can improve your formulations.
Below is a list of key scientific literature I referenced and relied upon in writing this article. These publications provide reliable scientific evidence for the efficacy and mechanisms mentioned in this article.
- Celanese. (2025). VitalDose® EVA pharmaceutical grade copolymer technical datasheet.
- European Pharmacopoeia Commission. (2024). Vinyl acetate monograph (9th ed.).
- Fritz, K. (1912). Über die polymerisation von vinylacetat. Berichte der Deutschen Chemischen Gesellschaft, 45(1), 184-190.
- Kim, J., & Park, S. (2024). Biodegradable EVA copolymers for long-acting drug delivery implants. Journal of Controlled Release, 368, 112-125.
- National Center for Biotechnology Information. (2022). Toxicological profile for vinyl acetate. U.S. Department of Health and Human Services.
- Sigma-Aldrich. (2025). Vinyl acetate ≥99.9% (GC) pharmaceutical grade safety data sheet.
- Wang, L., & Zhang, H. (2023). Green synthesis of vinyl acetate via bio-fermentation coupled with chemical catalysis. Journal of Industrial Microbiology & Biotechnology, 50(4), kuad025.